Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 61

1.

Synthesis and in vivo evaluation of 3,4-disubstituted gababutins.

Blakemore DC, Bryans JS, Carnell P, Field MJ, Kinsella N, Kinsora JK, Meltzer LT, Osborne SA, Thompson LR, Williams SC.

Bioorg Med Chem Lett. 2010 Jan 1;20(1):248-51. doi: 10.1016/j.bmcl.2009.10.121. Epub 2009 Oct 30.

PMID:
19910190
2.

Asenapine effects in animal models of psychosis and cognitive function.

Marston HM, Young JW, Martin FD, Serpa KA, Moore CL, Wong EH, Gold L, Meltzer LT, Azar MR, Geyer MA, Shahid M.

Psychopharmacology (Berl). 2009 Nov;206(4):699-714. doi: 10.1007/s00213-009-1570-z. Epub 2009 May 22.

3.

Synthesis and SAR of tolylamine 5-HT6 antagonists.

Singer JM, Wilson MW, Johnson PD, Graham SR, Cooke LW, Roof RL, Boxer PA, Gold LH, Meltzer LT, Janssen A, Roush N, Campbell JE, Su TZ, Hurst SI, Stoner CL, Schwarz JB.

Bioorg Med Chem Lett. 2009 May 1;19(9):2409-12. doi: 10.1016/j.bmcl.2009.03.077. Epub 2009 Mar 25.

PMID:
19346128
4.

Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias.

Ouattara B, Belkhir S, Morissette M, Dridi M, Samadi P, Grégoire L, Meltzer LT, Di Paolo T.

J Mol Neurosci. 2009 Jun;38(2):128-42. doi: 10.1007/s12031-008-9137-8. Epub 2008 Aug 14.

PMID:
18704766
5.

Normalization of GABAA receptor specific binding in the substantia nigra reticulata and the prevention of L-dopa-induced dyskinesias in MPTP parkinsonian monkeys.

Samadi P, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T.

Synapse. 2008 Feb;62(2):101-9.

PMID:
17992687
6.

mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys.

Samadi P, Grégoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, Di Paolo T.

Neurobiol Aging. 2008 Jul;29(7):1040-51. Epub 2007 Mar 13.

PMID:
17353071
7.

Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.

Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.

Synapse. 2006 Sep 1;60(3):239-50.

PMID:
16739115
8.

Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin.

Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.

Mov Disord. 2006 Jan;21(1):9-17.

PMID:
16127720
9.

Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein.

Belliotti TR, Capiris T, Ekhato IV, Kinsora JJ, Field MJ, Heffner TG, Meltzer LT, Schwarz JB, Taylor CP, Thorpe AJ, Vartanian MG, Wise LD, Zhi-Su T, Weber ML, Wustrow DJ.

J Med Chem. 2005 Apr 7;48(7):2294-307.

PMID:
15801823
10.

Subtype selective NMDA receptor antagonists: evaluation of some novel alkynyl analogues.

Kornberg BE, Nikam SS, Wright JL, Kesten SR, Meltzer LT, Coughenour L, Barr B, Serpa KA, McCormick J.

Bioorg Med Chem Lett. 2004 Mar 8;14(5):1213-6.

PMID:
14980668
11.

Orally active oxime derivatives of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one. Synthesis and pharmacological activity.

Venhuis BJ, Dijkstra D, Wustrow D, Meltzer LT, Wise LD, Johnson SJ, Wikström HV.

J Med Chem. 2003 Sep 11;46(19):4136-40.

PMID:
12954065
12.

Orally active analogues of the dopaminergic prodrug 6-(N,N-di-n-propylamino)-3,4,5,6,7,8-hexahydro-2H-naphthalen-1-one: synthesis and pharmacological activity.

Venhuis BJ, Dijkstra D, Wustrow DJ, Meltzer LT, Wise LD, Johnson SJ, Heffner TG, Wikström HV.

J Med Chem. 2003 Feb 13;46(4):584-90.

PMID:
12570379
13.

A new type of prodrug of catecholamines: an opportunity to improve the treatment of Parkinson's disease.

Venhuis BJ, Rodenhuis N, Wikström HV, Wustrow D, Meltzer LT, Wise LD, Johnson SJ, Pugsley TA, Sundell S, Dijkstra D.

J Med Chem. 2002 Jun 6;45(12):2349-51. Erratum in: J Med Chem 2002 Aug 29;45(18):4056.

PMID:
12036342
14.

NR2B selective NMDA receptor antagonists.

Nikam SS, Meltzer LT.

Curr Pharm Des. 2002;8(10):845-55. Review.

PMID:
11945135
15.

Pregabalin enhances nonrapid eye movement sleep.

Kubota T, Fang J, Meltzer LT, Krueger JM.

J Pharmacol Exp Ther. 2001 Dec;299(3):1095-105.

PMID:
11714899
16.

Mouse strains differ under a simple schedule of operant learning.

Baron SP, Meltzer LT.

Behav Brain Res. 2001 Jan 29;118(2):143-52.

PMID:
11164511
17.

Thiazoloindans and thiazolobenzopyrans: a novel class of orally active central dopamine (partial) agonists.

van Vliet LA, Rodenhuis N, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Haenen GR, Bast A.

J Med Chem. 2000 Sep 21;43(19):3549-57.

PMID:
11000009
18.

Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(heteroarylalkynyl)-4-benzylpiperidines.

Wright JL, Gregory TF, Kesten SR, Boxer PA, Serpa KA, Meltzer LT, Wise LD, Espitia SA, Konkoy CS, Whittemore ER, Woodward RM.

J Med Chem. 2000 Sep 7;43(18):3408-19.

PMID:
10978188
19.

Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).

van Vliet LA, Rodenhuis N, Dijkstra D, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, Huff RM, Svensson K, Sundell S, Lundmark M.

J Med Chem. 2000 Jul 27;43(15):2871-82.

PMID:
10956195
20.

Subtype-selective N-methyl-D-aspartate receptor antagonists: benzimidazalone and hydantoin as phenol replacements.

Schelkun RM, Yuen PW, Serpa K, Meltzer LT, Wise LD, Whittemore ER, Woodward RM.

J Med Chem. 2000 May 4;43(9):1892-7.

PMID:
10794706
21.

PD 158771, a potential antipsychotic agent with D2/D3 partial agonist and 5-HT(1A) agonist actions. II. Preclinical behavioral effects.

Corbin AE, Meltzer LT, Ninteman FW, Wiley JN, Christoffersen CL, Wustrow DJ, Wise LD, Pugsley TA, Heffner TG.

Neuropharmacology. 2000 Apr 27;39(7):1211-21.

PMID:
10760363
22.

PD 158771, a potential antipsychotic agent with D(2)/D(3) partial agonist and 5-HT(1A) agonist actions. I. Neurochemical effects.

Akunne HC, Zoski KT, Davis MD, Cooke LW, Meltzer LT, Whetzel SZ, Shih YH, Wustrow DJ, Wise LD, MacKenzie RG, Georgic LM, Heffner TG, Pugsley TA.

Neuropharmacology. 2000 Apr 27;39(7):1197-210.

PMID:
10760362
23.

Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.

Gregory TF, Wright JL, Wise LD, Meltzer LT, Serpa KA, Konkoy CS, Whittemore ER, Woodward RM.

Bioorg Med Chem Lett. 2000 Mar 20;10(6):527-9.

PMID:
10741546
24.

Discovery of subtype-selective NMDA receptor ligands: 4-benzyl-1-piperidinylalkynylpyrroles, pyrazoles and imidazoles as NR1A/2B antagonists.

Wright JL, Gregory TF, Boxer PA, Meltzer LT, Serpa KA, Wise LD.

Bioorg Med Chem Lett. 1999 Oct 4;9(19):2815-8.

PMID:
10522697
25.

Subtype-selective N-methyl-D-aspartate receptor antagonists: synthesis and biological evaluation of 1-(arylalkynyl)-4-benzylpiperidines.

Wright JL, Gregory TF, Bigge CF, Boxer PA, Serpa K, Meltzer LT, Wise LD, Cai SX, Hawkinson JE, Konkoy CS, Whittemore ER, Woodward RM, Zhou ZL.

J Med Chem. 1999 Jul 1;42(13):2469-77.

PMID:
10395488
26.
27.

Modulation of dopamine neuronal activity by glutamate receptor subtypes.

Meltzer LT, Christoffersen CL, Serpa KA.

Neurosci Biobehav Rev. 1997 Jul;21(4):511-8. Review.

PMID:
9195610
28.

Metabotropic glutamate receptor-mediated inhibition and excitation of substantia nigra dopamine neurons.

Meltzer LT, Serpa KA, Christoffersen CL.

Synapse. 1997 Jun;26(2):184-93.

PMID:
9131777
29.

Pharmacokinetics and pharmacodynamics of an investigational antipsychotic agent, CI-1007, in rats and monkeys.

Feng MR, Corbin AE, Wang Y, Christoffersen CL, Wiley JN, Strenkoski CA, Tucker EV, Ninteman FW, Meltzer LT, Heffner TG, Wright DS.

Pharm Res. 1997 Mar;14(3):329-36.

PMID:
9098876
30.

Aryl 1-but-3-ynyl-4-phenyl-1,2,3,6-tetrahydropyridines as potential antipsychotic agents: synthesis and structure-activity relationships.

Glase SA, Akunne HC, Heffner TG, Jaen JC, MacKenzie RG, Meltzer LT, Pugsley TA, Smith SJ, Wise LD.

J Med Chem. 1996 Aug 2;39(16):3179-87.

PMID:
8759640
31.
32.

CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.

Meltzer LT, Christoffersen CL, Corbin AE, Ninteman FW, Serpa KA, Wiley JN, Wise LD, Heffner TG.

J Pharmacol Exp Ther. 1995 Aug;274(2):912-20.

PMID:
7636754
34.

The discovery and structure-activity relationships of 1,2,3,6-tetrahydro-4-phenyl-1-[(arylcyclohexenyl)alkyl]pyridines. Dopamine autoreceptor agonists and potential antipsychotic agents.

Wright JL, Caprathe BW, Downing DM, Glase SA, Heffner TG, Jaen JC, Johnson SJ, Kesten SR, MacKenzie RG, Meltzer LT, et al.

J Med Chem. 1994 Oct 14;37(21):3523-33.

PMID:
7932581
35.

Pharmacological profile of the dopamine partial agonist, (+/-)-PD 128483 and its enantiomers.

Meltzer LT, Caprathe BW, Christoffersen CL, Corbin AE, Jaen JC, Ninteman FW, Pugsley TA, Serpa KA, Shih YH, Whetzel SZ, et al.

J Pharmacol Exp Ther. 1993 Sep;266(3):1177-89.

PMID:
8103791
37.

Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.

Pugsley TA, Christofferson CL, Corbin A, DeWald HA, Demattos S, Meltzer LT, Myers SL, Shih YH, Whetzel SZ, Wiley JN, et al.

J Pharmacol Exp Ther. 1992 Dec;263(3):1147-58.

PMID:
1361570
38.

Lack of involvement of haloperidol-sensitive sigma binding sites in modulation of dopamine neuronal activity and induction of dystonias by antipsychotic drugs.

Meltzer LT, Christoffersen CL, Serpa KA, Pugsley TA, Razmpour A, Heffner TG.

Neuropharmacology. 1992 Sep;31(9):961-7.

PMID:
1359446
39.

Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.

Caprathe BW, Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT, Parvez M.

J Med Chem. 1991 Sep;34(9):2736-46.

PMID:
1680195
40.

Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones.

Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT.

J Med Chem. 1991 Jan;34(1):248-56.

PMID:
1671416
41.

Synthesis and dopamine agonist properties of (+-)-trans-3,4,4a,10b-tetrahydro-4-propyl-2H,5H-[1]benzopyrano [4,3-b]-1,4-oxazin-9-ol and its enantiomers.

DeWald HA, Heffner TG, Jaen JC, Lustgarten DM, McPhail AT, Meltzer LT, Pugsley TA, Wise LD.

J Med Chem. 1990 Jan;33(1):445-50.

PMID:
1967318
42.

4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines: a novel class of compounds with central dopamine agonist properties.

Jaen JC, Wise LD, Caprathe BW, Tecle H, Bergmeier S, Humblet CC, Heffner TG, Meltzer LT, Pugsley TA.

J Med Chem. 1990 Jan;33(1):311-7.

PMID:
1967314
43.
44.

CI-943, a potential antipsychotic agent. III. Evaluation of effects on dopamine neuronal activity.

Meltzer LT, Christoffersen CL, Heffner TG, Freeman AS, Chiodo LA.

J Pharmacol Exp Ther. 1989 Oct;251(1):123-30.

PMID:
2571714
45.

CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.

Heffner TG, Downs DA, Meltzer LT, Wiley JN, Williams AE.

J Pharmacol Exp Ther. 1989 Oct;251(1):105-12.

PMID:
2571712
46.

Nicotine-induced tolerance and dependence in rats and mice: studies involving schedule-controlled behavior.

Rosecrans JA, Stimler CA, Hendry JS, Meltzer LT.

Prog Brain Res. 1989;79:239-48.

PMID:
2587745
47.

Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide.

Meltzer LT, Serpa KA, Moos WH.

Psychopharmacology (Berl). 1989;99(1):103-8.

PMID:
2506595
49.

Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.

Jaen JC, Wise LD, Heffner TG, Pugsley TA, Meltzer LT.

J Med Chem. 1988 Aug;31(8):1621-5.

PMID:
2899647
50.

Nicotine and arecoline as discriminative stimuli: involvement of a non-cholinergic mechanism for nicotine.

Meltzer LT, Rosecrans JA.

Pharmacol Biochem Behav. 1988 Mar;29(3):587-93.

PMID:
3362953

Supplemental Content

Loading ...
Support Center